IBD Live: Optimizing Treatment Now and in the Future

Register now for this complimentary event!

How can you increase your familiarity with the mechanisms of action, efficacy, and safety of emerging IBD therapies? This series will improve your confidence and competence in safely and appropriately using these agents in clinical practice as they become available.

Agenda

A 3-part Webinar series on emerging IBD therapies. Click on Event Dates to learn more about the specific agenda and faculty for each program. The series includes:

Part 1: Optimizing IBD Treatment: The Path to Remission (August 23)

Part 2: Advanced Treatment for IBD: New Targets, New Approaches (September 26)

Part 3: Clinical Impact of New Data From ACG and DDW (October 24)

Events

Date / Time
Event Details

Faculty

Faculty
Francis A. Farraye, MD, MSc

Professor of Medicine
Section of Gastroenterology
Boston University School of Medicine
Clinical Director
Section of Gastroenterology
Boston Medical Center
Boston, Massachusetts

Faculty
Gary R. Lichtenstein, MD

Professor of Medicine
Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
Philadelphia, Pennsylvania

Faculty
David A. Schwartz, MD, FACG, AGAF

Professor of Medicine
Department of Gastroenterology
Director, IBD Center
Vanderbilt University
Nashville, Tennessee

CME

Goal
The goal of this program is to increase physicians’ familiarity with the actions, efficacy, and safety of emerging IBD therapies to improve their confidence and competence in safely and appropriately using these agents in clinical practice as they become available.

Target Audience
This program is intended for gastroenterologists and other healthcare providers who care for patients with IBD.

Learning Objectives

  • Employ recommended strategies for treatment optimization in patients who do not achieve IBD remission with induction therapy or experience loss of therapeutic response with maintenance therapy
  • Describe the proinflammatory pathways of IBD that may be therapeutically targeted to advance treatments for IBD
  • Optimize management of IBD now and in the future with new and emerging therapies based on evaluation of available efficacy and safety data

Accreditation

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.